FOSUN HEALTH Logo

Nasopharyngeal Carcinoma Diagnosis

catalogue

Nasopharyngeal Carcinoma Diagnosis

Nasopharyngeal Carcinoma Diagnosis

A biopsy through the nose confirms the diagnosis; MRI of the nasopharynx and skull base stages it. Plasma EBV DNA adds something no scan can — a measurement of how much tumour is present.

Endoscopy: where the diagnosis is made

Nasopharyngoscopy is a clinic procedure. A thin flexible or rigid endoscope is passed along the floor of the nose, topical anaesthetic is used, and the nasopharynx is inspected from both sides. The examination takes minutes, and it is the step that turns a neck lump into a diagnosis rather than a referral.

What the examiner looks for is a mass on the side wall or roof of the nasopharynx, most often in the fossa of Rosenmüller. Early tumours can be subtle — a slight asymmetry, an area that bleeds on contact, a patch of altered mucosa — and an asymmetry is enough to justify a biopsy. A biopsy is taken from the primary site at the same sitting, and it is the primary tumour that must be sampled: a biopsy of the neck node alone confirms that the node is malignant but leaves the diagnosis incomplete, which changes the treatment plan.

MRI, not CT, for the primary tumour

Contrast-enhanced MRI of the nasopharynx, skull base and neck is the imaging standard for this disease, and the reason is specific. The questions that decide the stage are soft-tissue questions — has the tumour reached the parapharyngeal space, has it eroded the skull base, has it followed the nerves towards the cavernous sinus — and MRI answers them where CT is ambiguous.

The MRI also defines the radiotherapy target. Because the treatment is radiotherapy, the imaging is not only a staging tool but the plan itself: the radiation oncologist contours the tumour and the at-risk tissue directly onto the MRI. A study done elsewhere on a CT, or an MRI without the sequences needed for skull-base assessment, often has to be repeated here. PET-CT is used in addition, not instead, and its main purpose is to detect distant spread in bone, lung or liver in patients with advanced nodal disease.

Plasma EBV DNA: what it adds that imaging cannot

Epstein-Barr virus DNA can be measured in a blood sample, and in nasopharyngeal carcinoma it is released by the tumour cells themselves. That makes it a tumour marker in the truest sense: not a proxy for the tumour but a product of it, and one that reflects tumour burden rather than anatomy.

It has three uses. At diagnosis it is measured as a baseline and has prognostic value — a high viral load predicts a higher risk of recurrence independently of stage. During treatment the rate at which it falls is a measure of how well the tumour is responding. After treatment a rising level is often the earliest signal of recurrence, detectable months before a scan shows anything, which is why it is measured at each follow-up visit. In endemic regions it is also used to screen people without symptoms, which is discussed on the screening page.

Reading the pathology report

The pathology report does two jobs: it confirms the diagnosis and it places the tumour in a WHO group, which predicts behaviour and radiotherapy response.

  • WHO type I — keratinizing squamous cell carcinoma. Separately classed because its behaviour differs from the endemic types.
  • WHO type II — non-keratinizing, differentiated. Strongly EBV-associated and radiosensitive.
  • WHO type III — non-keratinizing, undifferentiated. The classic endemic type, the most radiosensitive, and the one most likely to present as a neck node.
  • EBV status on the tissue — usually reported as viral RNA or protein, and used to confirm the association.
  • Other types — basaloid squamous carcinoma or a salivary gland-type tumour, which are managed differently.

If the report says only squamous cell carcinoma without a WHO group, or does not mention EBV status, it is worth asking. The group affects the treatment intensity and the prognosis, and the EBV result is what distinguishes an endemic nasopharyngeal carcinoma from a keratinizing cancer arising in the same place, which behaves far less favourably.

Staging: the boundaries that change the plan

Staging follows the AJCC system, but in this disease three boundaries do most of the work:

  • The parapharyngeal space — the fat and muscle beside the nasopharynx. Involvement moves a tumour from T1 to T2, and it also means the radiotherapy target must extend laterally around the jaw.
  • The skull base — erosion of the bone beneath the nasopharynx makes it T3. It is the boundary between a straightforward plan and one built around critical structures.
  • Inside the skull, the cranial nerves, the orbit and the lower throat — any of these makes it T4, and they push the dose limits for the brain, the optic nerves and the temporal lobes to the centre of the planning discussion.

Nodes are staged separately, and the N categories in nasopharyngeal carcinoma differ from those used for other head and neck cancers because nodal involvement is so common and so prognostically important. Distant spread — most often bone, lung or liver — is looked for with PET-CT in patients with advanced neck disease, and it separates Stage IVB from the rest.

Arranging the work-up from abroad

Most of the diagnostic pathway can be begun in your own country, but three parts usually need to be done or repeated here, and knowing which saves a wasted trip.

The biopsy can be reviewed from the slides and the report, but if the tumour was diagnosed from a neck node alone, the primary still has to be found and sampled. MRI should include the nasopharynx, skull base and neck with contrast and the sequences needed to assess skull-base invasion; a scan done elsewhere without those sequences will be repeated. And baseline assessments before radiotherapy — audiometry, a dental assessment, thyroid function and, where relevant, an eye examination — are part of the preparation for treatment rather than optional extras, because they determine what has to be protected during planning.

Frequently Asked Questions

Can nasopharyngeal carcinoma be diagnosed from a blood test?

Not as a confirmation, but plasma EBV DNA testing has made blood testing genuinely useful in two ways. In high-risk populations it can be used as a screening test, flagging people who then need endoscopy — it detects the disease earlier than symptoms would. In patients already diagnosed it is used to measure tumour burden, to track the response to treatment and to detect recurrence early. What it cannot do is replace the biopsy, because a positive result still has to be confirmed by examining the nasopharynx and taking tissue.

Why do I need an MRI instead of a CT?

Because the decisions that stage this cancer are soft-tissue decisions. MRI shows whether the tumour has reached the parapharyngeal space, whether it has eroded the skull base and whether it is following the nerves towards the brain — distinctions that CT often cannot make clearly. MRI is also what the radiation oncologist contours the treatment plan on, so a good MRI here is not just a staging document; it is the treatment plan itself. If the scan was done elsewhere without the right sequences, it usually needs repeating.

Will the biopsy of my neck lump be enough?

It will tell you the lump is malignant, but it will not by itself complete the diagnosis. Nasopharyngeal carcinoma is diagnosed from the primary tumour in the nasopharynx, and it is that tissue which gives the WHO type and the EBV status that predict how the tumour will respond to radiotherapy. A neck node biopsy is still useful — it establishes the diagnosis and rules out lymphoma — but it should be accompanied by an examination and biopsy of the nasopharynx, which is where the treatment is aimed.

What does a plasma EBV DNA result mean?

It measures viral DNA released by the tumour into the blood, so a higher level generally means more tumour. At diagnosis it is a prognostic marker: a high baseline load predicts a higher risk of recurrence even after the stage is taken into account. During treatment, how quickly the level falls reflects how well the tumour is responding. After treatment, a rising level is often the first sign of recurrence — frequently months before anything appears on a scan — which is why it is checked at follow-up.

Patient Stories

Stories from our nasopharyngeal carcinoma programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

Have a neck lump that needs a diagnosis?

Send your nasopharyngoscopy findings, any biopsy report, the MRI images and your plasma EBV DNA result if it has been measured. Our head and neck team will return a written assessment within 48 hours of the file being complete — including whether the nasopharynx needs to be examined here and what the staging work-up still requires.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*